Tagged with EY

strategic levels Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also describes how the company’s new reagent facility in Germany will help bolster it domestically and regionally. Can you tell us…

Generics Earl Stanley Perez, General Manager of Meyerf Philippines, explains the importance of focusing on a few niches to succeed in a growing in a competitive market such as the Philippines, stressing the need for local companies to raise brand awareness and not only target the private sector but partner with…

Array   The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites the international life sciences com-munity to the island, the excitement was palpable. Foreign companies turned out in record numbers to…

Generics The CEO of Metiska Farma talks about coming back to Indonesia after studying in the US at Berkeley and MIT, to take over the company, and the company’s strategy of adding value through a portfolio of generics and OTC products. Can you begin by giving a brief introduction of Metiska…

Life Sciences James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech will be the leading industry in this new strategy and that less reliance on China will be necessary for an…

Ernst & Young LLP   Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada.   What do you see as the biggest challenges of life sciences clients in…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Ireland Can you please introduce yourself, and Ernst & Young’s life science practice in Ireland, to our readers? I am the managing partner of Ernst & Young (EY) in Ireland, responsible for both the Republic of Ireland and Northern Ireland.I have been with EY since the start of my professional career…

Ferring Pharmaceuticals Turkey The company entered the Turkish market in 2005, and made important product launches in 2008. You have been General Manager of Ferring Turkey over those last 7 years. Can you come back on the positive and negative experiences for you during this time? I believe that Ferring’s start in 2005…

DAIICHI SANKYO TURKEY Would you like to come back for our readers on the main milestones in Daiichi Sankyo’s development over the past few years in Turkey and how it positions itself in this market? Daiichi Sankyo entered the Turkish market four years ago. At the time, little did we know that we…

Pharmavision Turkey You have pharmaceuticals production in your background and have recently joined PharmaVision as General Manager. To what extent does this speak about the company’s direction? Could you elaborate on your career and key milestones that led you to become General Manager at PharmaVision? My career began after university, when I…

GSK Turkey Mr Fadıllıoğlu, after a previous position at Abbott, you were recently appointed head of GSK Turkey. How different is GSK as an organization? What new therapeutic areas, processes, or corporate culture did you have the chance to discover and to adapt to? The team members would be able to judge…